Pathkey.ai Ltd
Research Pathkey.ai Ltd (PKY) on Bullrun: market cap AUD 45.66M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPKY
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryHealth Information Services
- CurrencyAUD
- Market capAUD 45.66M
- Financial periodFY2025
Valuation Snapshot
latest market cap is AUD 45.66M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -0.01 | n/a | n/a | n/a |
| FY2024 | AUD 397.64K | -AUD 3.13M | -AUD 2.07M | 100.0% | -0.02 | AUD 374.65K | n/a | -AUD 90.16K |
| FY2023 | AUD 613.61K | -AUD 1.73M | -AUD 1.37M | 100.0% | -0.02 | AUD 452.88K | AUD 300.00K | -AUD 403.59K |
| FY2022 | AUD 880.76K | -AUD 2.09M | -AUD 1.53M | 100.0% | -0.03 | AUD 786.33K | n/a | AUD 267.01K |
| FY2021 | AUD 755.97K | -AUD 1.14M | -AUD 918.13K | 100.0% | n/a | AUD 2.32M | n/a | AUD 2.19M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | AUD 45.66M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Pathkey.ai Ltd
Pathkey.AI Ltd, a digital health company, involves artificial intelligence (AI) to improve clinical trials and predicting outcomes for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process. The company serves biopharma, MedTech, government, and healthcare organizations.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pathkey.ai Ltd's market cap?
Pathkey.ai Ltd's market capitalization is AUD 45.66M.
What does Pathkey.ai Ltd do?
Pathkey.AI Ltd, a digital health company, involves artificial intelligence (AI) to improve clinical trials and predicting outcomes for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process. The company serves biopharma, MedTech, government, and healthcare organizations. The company was formerly known as Opyl Limited and changed its name to Pathkey.AI Ltd in August 2025.